Uchida K, Itoyama T, Yamaguchi H
Teikyo University Institute of Medical Mycology.
Jpn J Antibiot. 1996 Aug;49(8):818-23.
In vitro antifungal activities of omoconazole nitrate (OMZ), a novel antifungal imidazole antimycotic drug, are examined against clinical isolates obtained from patients with cutaneous mycosis and its activity was compared with that of bifonazole (BFZ). The clinical isolates tested were 70 of dermatophytes including Trichophyton rubrum (47 isolates), T. mentagrophytes (22 isolates), Microsporum gypseum (1 isolate), and 27 isolates of Candida albicans. MIC values of OMZ to dermatophytes distributed in a range of < or = 0.04 to 0.63 microgram/ml were similar to those of BFZ (< or = 0.04 to 1.25 micrograms/ml). MIC values of OMZ to C. albicans were in a range of 0.16 to 2.5 micrograms/ml indicating that OMZ had more potent activities than BFZ (1.25 to 5 micrograms/ml). These results showed that in vitro antifungal activities of OMZ against clinical isolates of dermatophytes and C. albicans were greater than or similar to those of BFZ.
新型抗真菌咪唑类抗真菌药物硝酸奥莫康唑(OMZ)对从皮肤真菌病患者分离得到的临床菌株的体外抗真菌活性进行了检测,并将其活性与联苯苄唑(BFZ)进行了比较。所检测的临床菌株包括70株皮肤癣菌,其中红色毛癣菌47株、须癣毛癣菌22株、石膏样小孢子菌1株,以及27株白色念珠菌。OMZ对皮肤癣菌的最低抑菌浓度(MIC)值分布在≤0.04至0.63微克/毫升范围内,与BFZ(≤0.04至1.25微克/毫升)相似。OMZ对白色念珠菌的MIC值在0.16至2.5微克/毫升范围内,表明OMZ比BFZ(1.25至5微克/毫升)具有更强的活性。这些结果表明,OMZ对皮肤癣菌和白色念珠菌临床分离株的体外抗真菌活性大于或类似于BFZ。